BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25045997)

  • 21. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
    Comoglu T; Dilek Ozyilmaz E
    Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets.
    Gulsun T; Akdag Y; Izat N; Cetin M; Oner L; Sahin S
    Pharm Dev Technol; 2020 Oct; 25(8):999-1009. PubMed ID: 32431206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Technical scheme of real-time evaluation of traditional Chinese medicine orally disintegrating tablets].
    Qin D; Chen XD; Feng L; Gu JF; Yuan JR; Jia XB
    Zhongguo Zhong Yao Za Zhi; 2014 Dec; 39(24):4716-22. PubMed ID: 25898566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
    Shoukri RA; Ahmed IS; Shamma RN
    Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
    Dehghani H; Taheri A; Homayouni A
    Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
    Ahmed IS; Shamma RN; Shoukri RA
    Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets.
    Hooper P; Lasher J; Alexander KS; Baki G
    J Pharm Biomed Anal; 2016 Feb; 120():391-6. PubMed ID: 26774944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
    Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissolution testing of orally disintegrating tablets.
    Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
    J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
    Hobbs D; Karagianis J; Treuer T; Raskin J
    Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.
    Petrovick GF; Kleinebudde P; Breitkreutz J
    Eur J Pharm Biopharm; 2018 Jan; 122():137-145. PubMed ID: 29106946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further improvement of orally disintegrating tablets using micronized ethylcellulose.
    Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
    Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system.
    Aguilar-Díaz JE; García-Montoya E; Suñe-Negre JM; Pérez-Lozano P; Miñarro M; Ticó JR
    Eur J Pharm Biopharm; 2012 Apr; 80(3):638-48. PubMed ID: 22245156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor.
    Uchida T; Yoshida M; Hazekawa M; Haraguchi T; Furuno H; Teraoka M; Ikezaki H
    J Pharm Pharmacol; 2013 Sep; 65(9):1312-20. PubMed ID: 23927469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and evaluation of swelling induced-orally disintegrating tablets by microwave irradiation.
    Sano S; Iwao Y; Kimura S; Itai S
    Int J Pharm; 2011 Sep; 416(1):252-9. PubMed ID: 21763765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.
    Rahman Z; Siddiqui A; Khan MA
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
    Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
    Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The technologies used for developing orally disintegrating tablets: a review.
    Badgujar BP; Mundada AS
    Acta Pharm; 2011 Jun; 61(2):117-39. PubMed ID: 21684842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.